Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I dose-escalation study of CST-101 in patients with Advanced Renal Cell Carcinoma and Melanoma susceptible to immunotherapies.

Next Previous
Trial Profile

A phase I dose-escalation study of CST-101 in patients with Advanced Renal Cell Carcinoma and Melanoma susceptible to immunotherapies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CST 101 (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions

    • Most Recent Events

    • 17 Mar 2016 New trial record
    • 07 Feb 2016 Clinical data from the first 12 patients of the U.S. trial at Rush University Medical Center in Chicago has been announced recently, as per the University of Pittsburgh Medical Center (UPMC) media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top